Real-World Study Confirms Mepolizumab Effectiveness in Severe Rhinosinusitis With Nasal Polyps
Source Summary
A real-world study from Italy demonstrated that mepolizumab (Nucala) improved outcomes in adults with severe chronic rhinosinusitis with nasal polyps, with approximately one in five patients achieving remission. The treatment resulted in a reduction in nasal polyp scores.
Why it matters
The study provides clinical evidence that mepolizumab is effective for severe chronic rhinosinusitis with nasal polyps in real-world patient populations.
